A Discussion of Pharmacoeconomics Applied to Blood Substitutes
Pharmacoeconomics examines the costs and the consequences of health interventions. The results of pharmacoeconomic studies provide the economic reasons to use a particular product based on direct comparisons of costs and outcomes of competing products or interventions. In today’s healthcare marketplace, providers, and specifically managed care organizations (MCOs), are forced to make difficult choices about which products will be made available for use in their organizations. It is now imperative to make pharmacoeconomic study results available to decision makers for review in order to achieve product acceptance for use in most organizations (Clifton and Blumenschein 1995). Without the results of a pharmacoeconomic study at product launch, the likelihood of product use and acceptance in today’s market is extremely low. Therefore, implementing pharmacoeconomic studies during clinical trials is recommended.
KeywordsPrice Strategy Health Utility Index Pharmacoeconomic Study Blood Substitute Product Launch
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Bloom, B.S., and A.M. Fendrick
. Timing and timeliness in medical care evaluation. PharmacoEconomics
9: 183–187, 1996.PubMedCrossRefGoogle Scholar
Clemens, K., R. Townsend, F. Luscombe, J. Mauskopf, J. Osterhaus, and J. Bobula.
Methodological and conduct principles for pharmacoeconomic research. PharmacoEconomics
8: 169–174, 1995.PubMedCrossRefGoogle Scholar
Clifton, G.D., and K. Blumenschein.
The use of pharmaceuticals in critical care, the importance of outcome prediction models. PharmacoEconomics
7: 388–392, 1995.PubMedCrossRefGoogle Scholar
Statistical analysis in pharmacoeconomic studies. PharmacoEconomics
9: 506–516, 1996.PubMedCrossRefGoogle Scholar
Drummond, M., and L. Davies.
Economic analysis alongside clinical trials: revisiting the methodological issues. International Journal of Technology Assessment in Health Care
7: 561–573, 1991.PubMedCrossRefGoogle Scholar
Drummond, M.F., and G.L. Stoddart.
Economic analysis and clinical trials. Controlled Clinical Trials
5: 115–128, 1984.PubMedCrossRefGoogle Scholar
Eisenberg, J., H. Glick, K.
Schulman et al.
Pharmacoeconomics: economic evaluation of pharmaceuticals. In: Pharmcoepidemiology, 2nd ed.
(B. Strom, ed.). Chichester: John Wiley and Sons Ltd., 1994.Google Scholar
Feeny, D., W. Furlong, M. Boyle, and G.W. Torrance.
Multiattribute health status classification systems, health utilities index. PharmacoEconomics
7: 490–502, 1996.CrossRefGoogle Scholar
Hillman, A.L., and M.S. Kim.
Economic decision making in healthcare, a standard approach to discounting health outcomes. PharmacoEconomics
7: 198–205, 1995.PubMedCrossRefGoogle Scholar
Economic evaluation of drugs and its potential uses in policy making. PharmacoEconomics
8: 190–198, 1995.PubMedCrossRefGoogle Scholar
Mauskopf, J., K. Schulman, L. Bell, and H. Glick.
A strategy for collecting pharmacoeconomic data during Phase II/III clinical trials. PharmacoEconomics
9: 264–277, 1996.PubMedCrossRefGoogle Scholar
Rutten-van Molken, M., E. van Doorslaer, and R. van Vliet.
Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Economics
3: 333–345, 1994.CrossRefGoogle Scholar
Projecting future drug expenditures - 1996. American Journal of Health-System Pharmacists
53: 139–150, 1996.Google Scholar
Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology: a report on principles. Annals of Internal Medicine
122: 61–70, 1995.Google Scholar
Torrance, G.W., D. Blaker, A. Detsky, W. Kennedy, F. Schubert, D. Menon, P. Tugwell, R. Konchak, E. Hubbard, and T. Firestone.
Canadian guidelines for economic evaluation of pharmaceuticals. PharmacoEconomics
9: 535–559, 1996.PubMedCrossRefGoogle Scholar
Torrance, G.W., W. Furlong, D. Feeny, and M. Boyle.
Multi-attribute preference functions, health utilities index. PharmacoEconomics
7: 503–520, 1995.PubMedCrossRefGoogle Scholar
Wanke, L.A., and G.M. Ryan.
Strategic planning for applied pharmacoeconomics programs. Pharmacy Practice Management Quarterly
1 5: 64–74, 1996.PubMedGoogle Scholar
© Springer Science+Business Media New York 1997